Pierre Fabre and Iktos team up to accelerate AI-driven cancer drug discovery
Iktos will deploy its AI-driven tools to accelerate the identification of optimized small-molecule candidates against a currently undisclosed oncology target
Iktos will deploy its AI-driven tools to accelerate the identification of optimized small-molecule candidates against a currently undisclosed oncology target
Agreement to co-develop artificial intelligence (AI) technology for the application in peptide drug design
Iktos and Teijin Pharma will collaborate in developing new AI technology aiming to bring further improvement and speed to the drug design process
Subscribe To Our Newsletter & Stay Updated